Causes of Drug Shortages and Their Impact on Patient Care

By Dr. Priyom Bose, Ph.D.Reviewed by Lauren Hardaker

Prevalence and Factors Causing Global Drug Shortages
Consequences of Drug Shortages
Innovations and Strategies to Strengthen Drug Supply
Limitations of the Current R&D Landscape in Addressing Drug Shortages
References and Further Reading

Drug shortages pose a growing global healthcare challenge, driven by manufacturing disruptions, supply chain vulnerabilities, economic pressures, and regulatory barriers, resulting in treatment delays, medication errors, and increased healthcare costs. Emerging technologies, including artificial intelligence, automation, and real-time monitoring, offer promising solutions, but sustainable medicine availability requires coordinated regulatory, industrial, and healthcare strategies. 

Image credit: Zhenny-zhenny/Shutterstock.com

Medicines are fundamental to effective healthcare, and equitable access to them is a basic human right. However, drug shortages can critically impair the availability of essential treatments, threatening this core tenet of healthcare delivery. Understanding the underlying causes and far-reaching impacts of drug shortages is essential to developing robust solutions and ensuring a reliable supply of vital medications.¹

Prevalence and Factors Causing Global Drug Shortages

Drug shortages are a persistent global problem, affecting countries at every income level. In high-income regions like the UK, US, and Europe, shortages have become increasingly frequent and impactful. For example, in the UK, shortages have affected medications such as hormone replacement therapies and Attention Deficit Hyperactivity Disorder (ADHD) treatments.²

Germany and Austria face similar issues: an August 2023 German survey found 81% of physicians reported patients struggling to obtain medications, with over half observing patients requesting prescriptions in advance to maintain medicine supplies. The US also faces ongoing shortages of critical drugs, including antibiotics and cancer treatments.^2,3

The key factors linked to drug shortages include manufacturing disruptions, supply chain inefficiencies, business decisions, raw material shortages, regulatory hurdles, and economic pressures. In low- and middle-income countries (LMICs), additional factors, such as licensing barriers, local manufacturing constraints, drug smuggling, and restrictive government policies, exacerbate the crisis. Reliance on a limited number of manufacturers can further increase supply chain vulnerability.^2,4

The persistence and escalation of drug shortages worldwide underscore the urgent need for coordinated, multi-sector solutions to secure medicine supply chains and protect patient health.

Consequences of Drug Shortages

Drug shortages create serious challenges for patients, often forcing clinicians to use less effective alternatives, delay treatment, or leave some patients without viable options. The key consequences of drug shortages are listed below:³

When medicines run short, patients face the consequences. Download the PDF to examine the clinical risks and healthcare challenges.

Changes in medication dose and formulation

Drug shortages often force clinicians to change to alternative dosages or forms, which may require patients to take more tablets or undergo closer monitoring. This alteration could increase confusion and the risk of dosing errors. For children, the lack of liquid options may mean using alternative formulations that are more difficult to administer, which could further complicate care. Unfamiliar substitutes raise the chance of errors, adverse events, reduced efficacy, and, in rare cases, fatal outcomes, especially for those with infectious diseases or cancer.

Treatment delays or interruptions

Shortages can postpone or halt essential therapies, sometimes with no safe alternatives. This raises patient risk and can have broad public health impacts. For example, switching antibiotics to alternatives with a higher potential for resistance may fuel antimicrobial resistance, while painkiller shortages can perpetuate inadequate care and increase demand for alternative treatments.³

Financial effects

Alternative medicines may be costly, straining patients and healthcare systems financially. Shortage management also increases pharmacists' and physicians' workloads, as they must spend additional time identifying suitable alternatives.⁴

Innovations and Strategies to Strengthen Drug Supply

In response to increased pressure to provide safer, more effective, and reliably available medicines, the life sciences sector is rapidly evolving. Pharmaceutical companies are meeting these demands by harnessing advances in research and development (R&D), automation, and artificial intelligence (AI) to transform their supply chains.⁵

Continuous Monitoring: Safeguarding Drug Quality and Supply

Maintaining quality throughout the pharmaceutical supply chain is essential, particularly for temperature-sensitive drugs like insulin and vaccines. Periodic monitoring often misses crucial temperature fluctuations that can threaten product safety and lead to shortages. In contrast, continuous real-time monitoring, using IoT-enabled sensors, tracks conditions inside shipping containers, alerting operators to temperature deviations and enabling timely corrective action. This strategy can help reduce human error and prevent supply disruptions.⁶

Integrating automation, real-time data, and AI-powered analytics further transforms supply chain management. Automated platforms handle vast data streams, letting experts focus on strategic planning. At the same time, AI analytics detect emerging trends, forecast disruptions, and support rapid, data-driven responses. Together, these innovations streamline operations, enhance quality, and build a more resilient supply chain, helping reduce the risk of interruptions in medicine availability.⁷

AI-Driven R&D: Accelerating Discovery and Innovation

The integration of AI into life science R&D is transforming drug discovery and development. Today, predictive models can analyze extensive biological datasets and screen large libraries of potential drug candidates, while generative AI designs novel, optimized molecules and predicts their potential biological activity and toxicity in silico, well before experimental validation. AI-driven biotech innovation can accelerate drug-pipeline stages at reduced cost. Major investments in digital infrastructure and data sharing are fueling this transformation, drawing global venture capital and talent beyond traditional hubs.⁸

Revolutionizing Clinical Trials and Personalized Medicine

AI is transforming clinical trials, with the potential to improve their efficiency, safety, and participant selection. Machine learning models use historical patient data and digital twins to support trial design and explore the use of synthetic control arms, although these approaches require careful validation. Intelligent recruitment algorithms, analyzing appropriately governed patient databases, can help identify eligible patients for clinical trials.

Image credit: Mameraman/Shutterstock.com

This may improve recruitment efficiency, support more representative study populations, and potentially shorten development timelines. By analyzing genomic, lifestyle, and environmental data, AI also supports personalized treatment plans to improve efficacy and reduce side effects.^5,8

Limitations of the Current R&D Landscape in Addressing Drug Shortages

Even with significant progress, the current R&D landscape alone is insufficient to resolve drug shortages. Key barriers include outdated manufacturing technologies, fragile and complex supply chains, fixed production capacities, and highly regulated environments. Fragmented, non-standardized health data restricts the effectiveness of AI-driven solutions, while a shortage of interdisciplinary experts who can bridge biology and data science further hampers progress.⁹

Innovation is often slowed by risk-averse industry practices, increasingly complex regulatory requirements, and a lack of strong business incentives for adopting new technologies. Inconsistent global regulations add another layer of difficulty, making it harder to implement advanced manufacturing or flexible production.

Ultimately, overcoming these persistent barriers will require coordinated action across policy, regulation, and industry. Early-warning systems, improved information sharing, and more resilient manufacturing and distribution networks are important components of shortage prevention. A stable medicine supply requires collaboration across the entire healthcare ecosystem.⁹

References and Further Reading

1. Hogerzeil HV. Essential medicines and human rights: what can they learn from each other? Bull World Health Organ. 2006;84(5):371-5. DOI: 10.2471/BLT.06.031153, https://www.who.int/bulletin/volumes/84/5/371.pdf.
2. Shukar S, et al. Drug Shortage: Causes, Impact, and Mitigation Strategies. Front Pharmacol. 2021;12:693426. DOI: 10.3389/fphar.2021.693426, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.693426/full.
3. Rotter JM, Seifert R. Drug supply shortages and their perceived consequences for patients: a questionnaire survey of German and Austrian physicians. Eur J Clin Pharmacol. 2026;82(5):138. DOI: 10.1007/s00228-026-04052-4, https://link.springer.com/article/10.1007/s00228-026-04052-4.
4. Rose O, et al. Drug shortages: clinical implications and burdens - a trinational multiple-methods study including key stakeholders. J Pharm Policy Pract. 2025 Sep 23;18(1):2555731. DOI: 10.1080/20523211.2025.2555731, https://www.tandfonline.com/doi/full/10.1080/20523211.2025.2555731.
5. Debnath B, et al. The Pharmaceutical Industry's Future: How Artificial Intelligence is Transforming Medicine. Adv Pharm Bull. 2025 Sep 10;15(3):594-605. DOI: 10.34172/apb.025.45904, https://apb.tbzmed.ac.ir/Article/apb-45904.
6. Taj S. et al. IoT-based supply chain management: A systematic literature review. Internet of Things.2023; 24:100982. DOI: 10.1016/j.iot.2023.100982, https://www.sciencedirect.com/science/article/pii/S2542660523003056
7. Vadaga A K. Digital transformation in pharmaceuticals: The impact of AI on supply chain management. Intelligent Hospital. 2025; 1(1):100008. DOI: 10.1016/j.inhs.2025.100008, https://doi.org/10.1016/j.inhs.2025.100008
8. Ali S, et al. A New Era of Artificial Intelligence (AI): Transforming Drug Discovery and Development. J Med Chem. 2025 Nov 27;68(22):23643-23652. DOI: 10.1021/acs.jmedchem.5c03159, https://pubs.acs.org/doi/10.1021/acs.jmedchem.5c03159.
9. Yi Q, et al. How to alleviate the shortage: a scoping review of prevention and management of global drug shortages. BMC Public Health. 2026;26(1):1149. DOI: 10.1186/s12889-026-26834-2, https://link.springer.com/article/10.1186/s12889-026-26834-2.

Last Updated: Oct 22, 2026